|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Candesartan#Nonclinical Toxicology]] |
| {{Candesartan}}
| |
| {{CMG}}; {{AE}} {{SS}}
| |
| | |
| ==Nonclinical Toxicology==
| |
| | |
| ===Carcinogenesis, Mutagenesis, Impairment of Fertility===
| |
| | |
| There was no evidence of carcinogenicity when candesartan cilexetil was orally administered to mice and rats for up to 104 weeks at doses up to 100 and 1000 mg/kg/day, respectively. Rats received the drug by gavage, whereas mice received the drug by dietary administration. These (maximally-tolerated) doses of candesartan cilexetil provided systemic exposures to candesartan (AUCs) that were, in mice, approximately 7 times and, in rats, more than 70 times the exposure in man at the maximum recommended daily human dose (32 mg).
| |
| | |
| Candesartan and its O-deethyl metabolite tested positive for genotoxicity in the in vitro Chinese hamster lung (CHL) chromosomal aberration assay. Neither compound tested positive in the Ames microbial mutagenesis assay or the in vitro mouse lymphoma cell assay. Candesartan (but not its O-deethyl metabolite) was also evaluated in vivo in the mouse micronucleus test and in vitro in the Chinese hamster ovary (CHO) gene mutation assay, in both cases with negative results. Candesartan cilexetil was evaluated in the Ames test, the in vitro mouse lymphoma cell and rat hepatocyte unscheduled DNA synthesis assays and the in vivo mouse micronucleus test, in each case with negative results. Candesartan cilexetil was not evaluated in the CHL chromosomal aberration or CHO gene mutation assay.
| |
| | |
| Fertility and reproductive performance were not affected in studies with male and female rats given oral doses of up to 300 mg/kg/day (83 times the maximum daily human dose of 32 mg on a body surface area basis).<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = ATACAND (CANDESARTAN CILEXETIL) TABLET [ASTRAZENECA LP] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a73e1339-9643-4eea-2cbe-e879c88fb50e | publisher = | date = | accessdate = 20 February 2014 }}</ref>
| |
| | |
| ==References==
| |
| {{Reflist}}
| |
| | |
| {{Angiotensin II receptor antagonists}}
| |
| | |
| [[Category:Angiotensin II receptor antagonists]]
| |
| [[Category:Tetrazoles]]
| |
| [[Category:Benzimidazoles]]
| |
| [[Category:Ethers]]
| |
| [[Category:Carboxylic acids]]
| |
| [[Category:Biphenyls]]
| |
| [[Category:Cardiovascular Drugs]]
| |
| [[Category:Drugs]]
| |